Symbols

BIO

Bio-Rad Laboratories A·NYSE

--(--)

BIO fundamentals

BIO Q4 2025 Earnings

Bio-Rad Laboratories A (BIO) released its earnings on Feb 12, 2026: revenue was 693.20M (YoY +3.85%), beat estimates; EPS was 2.51 (YoY -13.45%), missed estimates.

Revenue / YoY

693.20M

+3.85%

EPS / YoY

2.51

-13.45%

Report date

Feb 12, 2026

BIO Earnings Call Summary for Q4,2025

Revenue Resilience: 2025 net sales $2.583B (0.7% YoY), with Q4 2025 non-GAAP EPS $2.51 vs. $2.90 in 2024.
ddPCR Success: QX700 platform drove mid-single-digit growth, with Stilla acquisition accreting 6-12 months earlier than expected.
Challenges Ahead: 2026 guidance for 0.5-1.5% revenue growth, with process chromatography expected to decline mid-teens due to regulatory changes.
Cash Flow Strength: 2025 free cash flow $375M (138% of non-GAAP net income), with $285M available for buybacks in 2026.
Strategic Focus: Operational efficiency, margin expansion, and selective M&A to drive long-term growth.

Earnings

EPS

Revenue

Revenue & Expenses

BIO has released its 2025 Q4 earnings report, with revenue of 693.20M, reflecting a YoY change of 3.85%, and net profit of 720.00M, showing a YoY change of 200.59%. The Sankey diagram below clearly presents BIO's revenue sources and cost distribution.

Key Indicators

Bio-Rad Laboratories A (BIO) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Bio-Rad Laboratories A (BIO)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Bio-Rad Laboratories A (BIO)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Bio-Rad Laboratories A (BIO)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown